Data dilemma

After successfully struggling for access to unpublished trial data, the authors of an updated Cochrane review on neuraminidase inhibitors (NAI) for influenza have been unfettered in their criticism of the drugs.

They conclude there is “no credible evidence that either oseltamivir or zanamivir reduce the risk of complications of influenza, particularly pneumonia, nor reduce risk of hospitalisation or death” even in those with higher risk of complications such as children with asthma or the elderly.

&ldquo